These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7557018)

  • 1. Oligonucleotide-mediated modulation of mammalian gene expression.
    Scanlon KJ; Ohta Y; Ishida H; Kijima H; Ohkawa T; Kaminski A; Tsai J; Horng G; Kashani-Sabet M
    FASEB J; 1995 Oct; 9(13):1288-96. PubMed ID: 7557018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation.
    Noonberg SB; Scott GK; Garovoy MR; Benz CC; Hunt CA
    Nucleic Acids Res; 1994 Jul; 22(14):2830-6. PubMed ID: 8052538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes.
    Lavrovsky Y; Chen S; Roy AK
    Biochem Mol Med; 1997 Oct; 62(1):11-22. PubMed ID: 9367793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential application of ribozymes for the treatment of hematological disorders.
    James HA
    J Leukoc Biol; 1999 Sep; 66(3):361-8. PubMed ID: 10496304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs.
    Zhang YC; Taylor MM; Samson WK; Phillips MI
    Methods Mol Med; 2005; 106():11-34. PubMed ID: 15375310
    [No Abstract]   [Full Text] [Related]  

  • 6. Nucleic-acid therapeutics: basic principles and recent applications.
    Opalinska JB; Gewirtz AM
    Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligodeoxynucleotides as antisense inhibitors of gene expression.
    Ghosh MK; Cohen JS
    Prog Nucleic Acid Res Mol Biol; 1992; 42():79-126. PubMed ID: 1574591
    [No Abstract]   [Full Text] [Related]  

  • 8. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 9. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonionic oligonucleotide analogs (Matagen) as anticodic agents in duplex and triplex formation.
    Ts'o PO; Aurelian L; Chang E; Miller PS
    Ann N Y Acad Sci; 1992 Oct; 660():159-77. PubMed ID: 1340119
    [No Abstract]   [Full Text] [Related]  

  • 11. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer.
    Nakata Y; Kim TK; Shetzline S; Gewirtz AM
    Crit Rev Eukaryot Gene Expr; 2005; 15(2):163-82. PubMed ID: 16022634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic oligonucleotides.
    Goodchild J
    Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic antisense and ribozymes.
    Rossi JJ
    Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligonucleotides as modulators of cancer gene expression.
    Curcio LD; Bouffard DY; Scanlon KJ
    Pharmacol Ther; 1997; 74(3):317-32. PubMed ID: 9352587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma.
    Okada T; Yamaguchi K; Yamashita J
    Growth Factors; 1994; 11(4):259-70. PubMed ID: 7779405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies.
    Jen KY; Gewirtz AM
    Stem Cells; 2000; 18(5):307-19. PubMed ID: 11007915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense oligonucleotides: promise and reality.
    Lebedeva I; Stein CA
    Annu Rev Pharmacol Toxicol; 2001; 41():403-19. PubMed ID: 11264463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of antioncogene ribozymes and antisense oligonucleotides in reversing drug resistance.
    Funato T
    Methods Mol Med; 2005; 106():215-33. PubMed ID: 15375319
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.